Placebo effect on progression and regression in NASH : Evidence from a meta‐analysis

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH

(2021) Abdul M. Majzoub et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients

(2021) Jee-Fu Huang et al.   Hepatology International

Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study

(2021) Takeshi Okanoue et al.   HEPATOLOGY RESEARCH

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

(2021) Stephen A. Harrison et al.   NATURE MEDICINE

Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

(2021) Veera Houttu et al.   Frontiers in Nutrition

Burden of Disease due to Nonalcoholic Fatty Liver Disease

(2020) Mark D. Muthiah et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

(2020) Vlad Ratziu et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

How are systematic reviews of prevalence conducted? A methodological study

(2020) Celina Borges Migliavaca et al.   BMC Medical Research Methodology

Hepatic molecular signatures highlight the sexual dimorphism of Non‐Alcoholic SteatoHepatitis (NASH)

(2020) Jimmy Vandel et al.   HEPATOLOGY

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study

(2020) Philip N. Newsome et al.   JOURNAL OF HEPATOLOGY

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum

(2020) Oliver Glass et al.   JOURNAL OF HEPATOLOGY

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

(2020) Qing Ye et al.   Lancet Gastroenterology & Hepatology

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank

(2020) Ryan W. Walker et al.   JOURNAL OF HEPATOLOGY

Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

(2020) Jonathan G. Stine et al.   Clinical Gastroenterology and Hepatology

Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019

(2020) Sonia Wang et al.   PLoS One

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex Differences in NAFLD : State of the Art and Identification of Research Gaps

(2019) Amedeo Lonardo et al.   HEPATOLOGY

Racial and Ethnic Disparities in Adult Obesity in the United States: CDC’s Tracking to Inform State and Local Action

(2019) Ruth Petersen et al.   Preventing Chronic Disease

Seriously misleading results using inverse of Freeman‐Tukey double arcsine transformation in meta‐analysis of single proportions

(2019) Guido Schwarzer et al.   Research Synthesis Methods

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

(2019) Fernando Bril et al.   DIABETES CARE

Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH

(2019) Rohit Loomba et al.   HEPATOLOGY

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

(2019) Naga Chalasani et al.   GASTROENTEROLOGY

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis

(2018) Ma Ai Thanda Han et al.   Clinical Gastroenterology and Hepatology

Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis

(2018) Nicole E. Rich et al.   Clinical Gastroenterology and Hepatology

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

(2018) Stephen A. Harrison et al.   GASTROENTEROLOGY

Determinants of fibrosis progression and regression in NASH

(2018) Detlef Schuppan et al.   JOURNAL OF HEPATOLOGY

Noninvasive biomarkers in NAFLD and NASH — current progress and future promise

(2018) Vincent Wai-Sun Wong et al.   Nature Reviews Gastroenterology & Hepatology

Fixed and random effects models: making an informed choice

(2018) Andrew Bell et al.   QUALITY & QUANTITY

Treatment of NAFLD with diet, physical activity and exercise

(2017) Manuel Romero-Gómez et al.   JOURNAL OF HEPATOLOGY

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis

(2017) Stuart McPherson et al.   PLoS One

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

(2017) Tisha R Joy et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide

(2017) Mikhaïl Van Herck et al.   Nutrients

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial

(2016) Monize Aydar Nogueira et al.   CLINICAL NUTRITION

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort

(2016) Veronica Wendy Setiawan et al.   HEPATOLOGY

Exercise in NAFLD: Just do it

(2016) Shelley E. Keating et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

(2015) Guillaume Lassailly et al.   GASTROENTEROLOGY

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012

(2015) Andy Menke et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

(2015) Srinivasan Dasarathy et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

(2015) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis

(2015) Yun-Hua Li et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

(2014) Joanna IntHout et al.   BMC Medical Research Methodology

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias

(2014) James P. Hunter et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

(2012) Thuy-Anh Le et al.   HEPATOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial

(2011) Claudia O. Zein et al.   HEPATOLOGY

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

(2010) Ulrich F. H. Leuschner et al.   HEPATOLOGY

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

(2010) Elizabeth M. Brunt et al.   HEPATOLOGY

Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease

(2010) Ravi Juluri et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Prevalence, gender, ethnic variations, and prognosis of NASH

(2010) Etsuko Hashimoto et al.   JOURNAL OF GASTROENTEROLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

(2009) Manal F. Abdelmalek et al.   HEPATOLOGY

Treatment of nonalcoholic steatohepatitis with colestimide

(2009) Makiko Taniai et al.   HEPATOLOGY RESEARCH

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis

(2009) Austin Nelson et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

(2009) William W. Shields et al.   Therapeutic Advances in Gastroenterology

Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials

(2008) Rohit Loomba et al.   Clinical Gastroenterology and Hepatology

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY